EMail Discussion List
The discussion threads and CPNP Email Discussion List subscriptions are available to currently active CPNP members for the purpose of communicating with other CPNP members on matters regarding psychiatric and neurologic pharmacy or medical issues.
- The CPNP email discussion list should not be used for individual or personal matters meaning that personal messages should not be posted to the list.
- Please note that when you reply to the CPNP email discussion list, your message will be sent only to the sender of the message. You are encouraged to select ”reply all” so that all list participants benefit from your comments.
- If, after posting a message you receive a reply off list, please do not repost the reply to the list without the permission of the sender.
- The CPNP email discussion list does allow attachments, which are scanned for viruses by a third-party service, but users are still responsible for the security of their own computers.
- Total size of each email message must not exceed 300 kilobytes.
Please remember that any information disclosed through electronic means is very easy to distribute and you should assume that anything you post will become public domain. You should carefully consider what information you include in your messages.
- CPNP members may not post any material regarding specific prices or fees charged or paid, market shares, or profit margins.
- Members are not allowed to post any sensitive or confidential information.
- Job posting by CPNP members should be posted through the job opportunities interface available on the CPNP website rather than through the email list. Once a job is posted, an announcement is automatically sent to the list.
- Please note that the views expressed on the CPNP Email Discussion List are considered personal opinions or statements of the sender and do not reflect official CPNP policies and/or positions, nor do they reflect any affiliations with the pharmaceutical industry unless clearly labeled as such.
- CPNP does not welcome unsolicited communications for commercial purposes from its members (or nonmembers) to any other CPNP members as a result of discussions on the CPNP Email Discussion List.
- In addition, due to the nature of the CPNP email discussion list, pharmacists working in industry may be limited in their discussion of clinical issues as this may be interpreted as representing or marketing an individual’s company policy versus his/her personal opinion.
- If members post information about cases involving adverse events from certain medications, pharmaceutical industry pharmacists may be compelled to report the adverse events to the manufacturing company, and/or to contact the individuals posting the message off of the email discussion list. It is important for members employed by the pharmaceutical industry to follow their individual company compliance policies when communicating with CPNP members.
Email discussion lists are not moderated by CPNP and CPNP has no control or responsibility for the accuracy of the information presented.
- It is up to the CPNP member that is submitting a message to an email discussion list to ensure that the information is accurate (providing a citation when appropriate), does not violate any laws, and doesn't contain any offensive language or comments.
- Discussions of boycotts, blacklisting, or negative personal opinions of individuals or suppliers is unlawful and will not be tolerated.
- It will also be assumed that permission has been obtained from copyright owners when members post copyright-protected information. In addition, CPNP will not be held liable for damages that result from information posted on the email discussion list.
- Nothing in the policy should be interpreted as an attempt to limit discussion of controversial topics or suppress an unpopular minority opinion, only that such discussions be civilized and orderly.
If a member's submissions violate this policy and a private warning does not modify their submissions, then CPNP will suspend their subscription to the CPNP Email Discussion List for a period of 1 month. If an additional warning is required after reinstatement, the individual’s CPNP Email Discussion List privileges will be cancelled. The decision to cancel a CPNP member's subscription may be appealed to the CPNP Board of Directors, but the Board decision will be final and will appear in the minutes of the Board of Director's meeting. CPNP email announcements are moderated and reflect the official position of the CPNP Board of Directors.
CPNP Email Discussion List Rules
- Do not attack others. The discussions on the CPNP Email Discussion List are meant to stimulate conversation, not to create contention. Let others have their say, just as you may.
- Do not post commercial messages on any CPNP Email Discussion List. Contact people directly with product and service information you want to share.
- Use caution when discussing products. Information posted on the CPNP Email Discussion List is available for all to see, and comments are subject to libel, slander, and antitrust laws.
- All defamatory, abusive, profane, threatening, offensive, or illegal materials are strictly prohibited. Do not post anything in a CPNP Email Discussion List message that you would not want the world to see or that you would not want anyone to know came from you.
- Remember that CPNP and other e-mail list participants have the right to reproduce postings to the CPNP Email Discussion List.
CPNP Email Discussion List Etiquette
- List your affiliation and the primary site/city you work from.
- Do not use all capital letters for more than a word.
- Insert a blank line between paragraphs.
- Surround URLs with angle brackets to avoid problems at line breaks.
- Include a signature tag on all messages. Include your name, affiliation, location, and e-mail address.
- State concisely and clearly the topic of your comments in the subject line. This allows members to respond more appropriately to your posting and makes it easier for members to search the archives by subject.
- Include only the relevant portions of the original message in your reply. Delete any header information, and put your response before the original posting.
- Send a message to the entire list when it contains information that everyone can benefit from.
- Send messages such as "thanks for the information" or "me, too" to individuals--not to the entire list. Do this by using your e-mail application's forwarding option and typing in or cutting and pasting in the e-mail address of the individual to whom you wish to respond.
- Do not send administrative messages, such as “remove me from the list”, through the CPNP Email Discussion List. Instead, use the membership update interface or an email to the office to make your request .
- Warn other CPNP Email Discussion List subscribers of lengthy messages either in the subject line or at the beginning of the message body with a line that says "Long Message."
CPNP Email Discussion List Member Surveys
Requests to survey CPNP members for research purposes are received by CPNP. The CPNP Board reviews each request individually and requires the following:
- The person posting the survey must be a member of CPNP or working with a member of CPNP on the research study. One person involved in the research study must be an active or associate member of CPNP.
- Evidence of IRB approval must be provided.
- The survey must be reviewed and approved by a minimum of 2 members of the Board of Directors.
- A disclaimer must be included indicating CPNP’s lack of involvement and endorsement of the survey and research product must be included in the body of the email at the beginning of the email as follows:
CPNP member participation in this research project is requested by the researcher (POSTING NAME and ACTIVE MEMBER NAME) and was approved on DATE by CPNP Board of Director members NAME ONE and NAME TWO The distribution of this survey request does not represent a request or endorsement by the CPNP board or CPNP as an organization. This survey research has been approved by the INSTITUTION NAME IRB: APPROVAL NUMBER on DATE by CONTACT NAME. No industry funding has been received for this research project